Last edition
News about "Molecular Clamp technology"
Sanofi to Acquire Vicebio for USD 1.6 Billion
Sanofi has entered into a definitive agreement to acquire Vicebio Ltd., a biopharma company developing next-generation respiratory vaccines, in a deal worth up to USD 1.6 billion, including an upfront payment of USD 1.15 billion.
Molecular Clamp Technology | 22/07/2025 | By Mrinmoy Dey | 107
Vicebio Raises USD 100 Million in Series B Financing Round
Vicebio is developing next-generation vaccines for respiratory viruses utilising its proprietary Molecular Clamp technology, discovered at The University of Queensland.
Molecular Clamp Technology | 23/09/2024 | By Aishwarya | 327
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy